Tyme Technologies, Inc., a clinical-stage biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. The company also offers TYME-18, a CMBT compound that is in preclinical stage for the treatment of solid tumors. Tyme Technologies, Inc. has a research collaboration with NYU Langone Health to advance the development of treatments for patients with metastatic cancers, including pancreatic cancer, as well as with Mayo Clinic; and a strategic collaboration with Eagle Pharmaceuticals, Inc. to advance oral SM-88 for the treatment of patients with cancer. The company was formerly known as Global Group Enterprises Corp. Tyme Technologies, Inc. was founded in 2011 and is headquartered in New York, New York.
Search:
You do not have permission to access this chart.
Please Sign Up or Login
News for Tyme Technologies, Inc. (TYME)
minutes ago | Banggood.com
58 minutes ago | Aliexpress.com
5 days ago | Business Wire
a week ago | Business Wire
2 weeks ago | Benzinga
2 weeks ago | InvestorPlace
2 weeks ago | Pulse2
2 weeks ago | Business Wire
2 months ago | Benzinga
2 months ago | Business Wire
2 months ago | Business Wire
3 months ago | Business Wire